La EMA ha recomendado autorizar el inhibidor de JAK1 Povofortay (povorcitinib) para la hidradenitis supurativa, una enfermedad autoinflamatoria crónica de la piel.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2026 18 September 2026 https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2026?&utm_medium=email&_hsenc=p2ANqtz-9QrJYMpiU78Fj5MKeoFNtEAERjOMyDIyZ8Xb7ov9hHE8ZUBGrvTxxHdVZRH7U6pBV2w8oo99elTlqf8Rqf-I7W8qPR5g&_hsmi=146512528&utm_content=146523058&utm_source=hs_email